A new global review from the University of East Anglia, Holland & Barrett, and the University of Southampton has delivered a wake-up call. Three-quarters of the world is not meeting recommended omega-3 intake.
The review shows that 76% of people worldwide fall short of EPA and DHA recommendations, across all life stages. This isn’t a small nutritional slip — it’s a major public health gap.
Omega-3 supports the body at every stage of life. Key benefits include:
The problem? Most people simply aren’t consuming enough oily fish or supplements to reach recommended levels.
Prof Anne Marie Minihane from UEA explains it clearly: Most people are nowhere close to what science recommends. The solution lies in easier and more sustainable omega-3 options, including enriched foods and supplements. This shift can help populations achieve the proven benefits of higher omega-3 intake.
Another issue is inconsistent global guidance. Different countries recommend different intake levels, creating confusion for consumers, practitioners, and policymakers.
The review aims to create clarity, especially for regions outside Europe and North America—such as Latin America and India, where guidance remains limited.
The review highlights the most common targets:
These levels are achievable through oily fish like salmon or mackerel — or supplements when diet falls short.
Populations struggle to meet omega-3 targets for several reasons:
These hurdles leave billions without adequate intake.
This review, published in Nutrition Research Reviews, presents the first global picture of omega-3 guidelines for healthy populations. Its goal is simple: Bridge the gap between science, public health policy, and real-world intake.
Sun Pharma has launched Ilumya (tildrakizumab) in India — a global biologic used for moderate-to-severe plaque psoriasis. Already trusted in 35 countries, Ilumya is known for its high efficacy, long-lasting skin clearance, and excellent safety profile.
Ilumya is a novel IL-23 inhibitor. It blocks the p19 subunit of IL-23, disrupting inflammatory pathways that drive psoriasis. Simple dosing. Strong outcomes. Sustained control.
Kirti Ganorkar, Sun Pharma’s MD, highlights its global success and ability to deliver meaningful relief to patients struggling with recurrent flares and poor disease control.
Sun Pharma studied Ilumya in 115 Indian patients.
The results were impressive:
Patients received three injections over 16 weeks, followed by monitoring up to Week 28.
There were no immunogenicity concerns, and quality-of-life scores improved significantly.
Dr B.S. Chandrashekar, a phase-3 trial investigator, emphasized the drug’s impact on long-term disease control.
Psoriasis affects 0.44–2.8% of India’s population. It is more than a skin condition — it is a systemic inflammatory disease linked to metabolic and cardiovascular risks.
Many Indian patients remain poorly controlled due to:
This creates an urgent need for targeted, durable, low-maintenance therapies like Ilumya.
Ilumya is the first IL-23 inhibitor with five years of continuous study data. The pivotal reSURFACE program enrolled over 1,800 patients across 200+ global sites. The takeaway: Ilumya maintains high efficacy and safety over years of use.
As the world’s leading specialty generics company, Sun Pharma continues to expand its innovative portfolio. Its launch of Ilumya in India bridges a long-standing treatment gap for psoriasis patients seeking safer, long-term disease control.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!